The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 4 rounds in the feed, most often at Series A and in Biotech.
digitalisventures.comRounds from 2022-10-14 to 2026-11-05
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
T-Therapeutics A biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases | Series B Verified against 1 of 65 sources | $133M | 2026-11-05 | [ PART ] |
Enveda Biosciences A clinical-stage biotechnology company that uses AI to discover medicines from life's chemistry | Series E |
| $311M |
| 2026-09-23 |
| [ PART ] |
T-Therapeutics A biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $59.8M | 2023-11-15 | [ LEAD ] |
Novartis-partnered biotech A biotechnology company pioneering the discovery of precision covalent medicines | Series A Verified against 2 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $70M | 2022-10-14 | [ PART ] |